Insider · CIK 0001522751

DAVE KAUSHIK J

Reports to the SEC for 2 companies · EWING, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001522751

Forms 4 and 5

Insider transactions

28 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2017-03-14	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Director, CEO and Interim CFO	AAward	+250K sh	$1.39	+$348K	250,000
2016-04-15	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Director, CEO and Interim CFO	AAward	+400K sh	$1.99	+$796K	400,000
2016-04-14	ATNMActinium Pharmaceuticals, Inc.P Purchase	Director, CEO and Interim CFO	PPurchase	+8,000 sh	$2.02	+$16.2K	86,500
2016-04-14	ATNMActinium Pharmaceuticals, Inc.P Purchase	Director, CEO and Interim CFO	PPurchase	+2,000 sh	$2.01	+$4,020	88,500
2015-05-07	ATNMActinium Pharmaceuticals, Inc.D Disposition to Issuer	Director, CEO and Interim CFO	DDisposition to Issuer	−68K sh	$2.45	−$167K	73,083
2015-05-07	ATNMActinium Pharmaceuticals, Inc.F Tax Payment	Director, CEO and Interim CFO	FTax Payment	−12.5K sh	$2.45	−$30.6K	85,583
2015-05-07	ATNMActinium Pharmaceuticals, Inc.D Disposition to Issuer	Director, CEO and Interim CFO	DDisposition to Issuer	−25K sh	$2.45	−$61.3K	85,583
2015-05-07	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Director, CEO and Interim CFO	AAward	+82.1K sh	$2.52	+$207K	82,128
2015-05-07	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Director, CEO and Interim CFO	AAward	+63.1K sh	$2.52	+$159K	63,063
2015-05-07	ATNMActinium Pharmaceuticals, Inc.F Tax Payment	Director, CEO and Interim CFO	FTax Payment	−7,083 sh	$2.45	−$17.4K	57,083
2015-05-07	ATNMActinium Pharmaceuticals, Inc.D Disposition to Issuer	Director, CEO and Interim CFO	DDisposition to Issuer	−27.5K sh	$2.45	−$67.4K	57,083
2015-05-07	ATNMActinium Pharmaceuticals, Inc.F Tax Payment	Director, CEO and Interim CFO	FTax Payment	−16K sh	$2.45	−$39.2K	73,083
2015-02-18	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Director, CEO and Interim CFO	AAward	+150K sh	$3.58	+$537K	150,000
2013-12-16	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Director, CEO and Interim CFO	AAward	+675K sh	$6.70	+$4.52M	675,000
2013-06-03	ANTARES PHARMA, INC.Stock Option (right to buy)M Exercise/Conversion	Executive Vice President	MExercise/Conversion	−48K sh	—	—	647,195
2013-06-03	ANTARES PHARMA, INC.S Sale	Executive Vice President	SSale	−48K sh	$4.01	−$193K	265,028
2013-06-03	ANTARES PHARMA, INC.M Exercise/Conversion	Executive Vice President	MExercise/Conversion	+48K sh	$0.47	+$22.6K	313,028
2013-05-22	ANTARES PHARMA, INC.A Award	Executive Vice President	AAward	+29.5K sh	—	—	235,567
2013-05-22	ANTARES PHARMA, INC.A Award	Executive Vice President	AAward	+29.5K sh	—	—	265,028
2013-05-22	ANTARES PHARMA, INC.Stock Option (right to buy)A Award	Executive Vice President	AAward	+52.1K sh	—	—	695,195
2013-05-06	ANTARES PHARMA, INC.S Sale	Executive Vice President	SSale	−12K sh	$4.02	−$48.2K	206,106
2013-05-06	ANTARES PHARMA, INC.M Exercise/Conversion	Executive Vice President	MExercise/Conversion	+12K sh	$0.47	+$5,640	218,106
2013-05-06	ANTARES PHARMA, INC.STOCK OPTION (RIGHT TO BUY)M Exercise/Conversion	Executive Vice President	MExercise/Conversion	−12K sh	—	—	643,112
2012-07-06	ANTARES PHARMA, INC.A Award	Executive Vice President	AAward	+21.1K sh	—	—	213,721
2012-07-06	ANTARES PHARMA, INC.Stock Option (right to buy)A Award	Executive Vice President	AAward	+34.1K sh	—	—	655,112
2012-05-17	ANTARES PHARMA, INC.Stock Option (right to buy)A Award	Executive Vice President	AAward	+70K sh	—	—	621,000
2012-02-10	ANTARES PHARMA, INC.A Award	Executive Vice President	AAward	+16.9K sh	—	—	192,594
2011-09-09	ANTARES PHARMA, INC.A Award	Executive Vice President	AAward	+34.2K sh	—	—	175,707

Recent filings

Accepted (ET)
Mar 164
Actinium Pharmaceuticals, Inc.0001213900-17-002501
SEC(opens sec.gov)
Apr 184
Actinium Pharmaceuticals, Inc.0001213900-16-012634
SEC(opens sec.gov)
May 224
Actinium Pharmaceuticals, Inc.0001213900-15-004135
SEC(opens sec.gov)
Mar 164
Actinium Pharmaceuticals, Inc.0001213900-15-001810
SEC(opens sec.gov)
Dec 244
Actinium Pharmaceuticals, Inc.0001213900-13-007392
SEC(opens sec.gov)
Jun 54
ANTARES PHARMA, INC.0001181431-13-032916
SEC(opens sec.gov)
May 244
DAVE KAUSHIK J0001181431-13-030732
SEC(opens sec.gov)

Companies

Address

250 PHILLIPS BLVD SUITE 290

EWING, NJ, 08618